Drug Profile
AGN 201781
Alternative Names: AGN201781Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals; Allergan
- Developer Allergan
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 08 Oct 2015 AGN 201781 is available for licensing as of 26 Feb 2015. http://www.acadia-pharm.com/
- 08 Mar 2005 Phase-I clinical trials in Pain in USA (PO)